33 completed, 15 active not recruiting, 12 terminated, 5 recruiting. 71 Phase 3, 13 Phase 2.
Follow Rituxan: new trials by email Literature Review of Rituxan trials Research Report on Rituxan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Sonrotoclax, Obinutuzumab, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 630 | 2025-06-11 | 2026-10-23 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Recruiting | National Cancer Institute (NCI) | 600 | 2024-10-23 | 2026-10-28 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 216 | 2024-02-15 | 2026-05-11 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Odronextamab, Lenalidomide, Rituximab - Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 580 | 2023-12-28 | 2026-10-07 |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 822 | 2023-12-12 | 2026-10-06 |
| A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 733 | 2023-11-14 | 2026-02-06 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma parsaclisib, rituximab, bendamustine - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Incyte Corporation | 2022-03-11 | 2022-04-29 | |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Zanubrutinib, Rituximab, Lenalidomide - Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 799 | 2022-03-10 | 2026-10-15 |
| Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Rituximab, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 40 | 2022-02-28 | 2025-08-01 |
| Rituxmab Versus IL-6 in Treating ILD Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2021-12-01 | 2023-11-15 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-10-01 |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 282 | 2021-09-23 | 2026-09-25 |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 600 | 2021-09-20 | 2026-01-29 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | Hoffmann-La Roche | 166 | 2020-05-28 | 2026-03-03 |
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 |
Showing 20 of 71. Sign in to see all of them.
Lymphoma, Non-Hodgkin (18) · Lymphoma, Follicular (16) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Lymphoma (8) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Mantle-Cell (7) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, B-Cell (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Arthritis, Rheumatoid (2) · Burkitt Lymphoma (2) · Granulomatosis with Polyangiitis (2) · Hematologic Diseases (2) · Lung Diseases, Interstitial (2) · Microscopic Polyangiitis (2)
National Cancer Institute (NCI) (9) · Hoffmann-La Roche (6) · Regeneron Pharmaceuticals (4) · Celltrion (3) · German CLL Study Group (3) · BeOne Medicines (2) · Celgene (2) · Genentech, Inc. (2) · Incyte Corporation (2) · Loxo Oncology, Inc. (2) · Northwestern University (2) · SWOG Cancer Research Network (2) · SecuraBio (2) · Acerta Pharma BV (1) · Amgen (1)
United States (49) · Australia (23) · Italy (23) · Canada (20) · France (19) · Spain (19) · Germany (18) · South Korea (15) · Poland (14) · United Kingdom (14) · Belgium (13) · Brazil (13) · Czechia (13) · Austria (11) · Israel (11)
Hagop Youssoufian, MD (2) · Richard Burt, MD (2) · Alessia Fornoni, M.D. (1) · Barbara Eichhorst, MD (1) · Barbara Eichhorst, MD, Prof. (1) · Barbara Konkle, MD (1) · Bernhard Hauns, MD (1) · Chitra M. Hosing, MD (1) · Christopher Hillyer, MD (1)
PMID 27695295, PMID 20039413, PMID 20647199, PMID 21073974, PMID 22231479, PMID 22975753, PMID 23233710, PMID 23754238, PMID 23902481, PMID 24591201, PMID 24720836, PMID 25047592, PMID 25343233, PMID 25686644, PMID 25776953, PMID 26387933, PMID 26621483, PMID 26867033, PMID 26875824, PMID 27696762, PMID 28031173, PMID 28270229, PMID 28712940, PMID 29356608, PMID 30010481, PMID 30089664, PMID 30184451, PMID 30389036, PMID 30501481, PMID 30719632, PMID 30811293, PMID 30897038, PMID 30934066, PMID 31184752, PMID 31216123, PMID 31365801, PMID 31573078, PMID 31806605, PMID 32071431, PMID 32589970, PMID 32601378, PMID 32612255, PMID 32673385, PMID 32810220, PMID 33044684, PMID 33288485, PMID 33439748, PMID 33649098, PMID 34134469, PMID 34274940
U10CA021115 (3), U10CA180820 (3), U10CA180821 (3), U10CA180888 (3), 2014 (2), 2015 (2), 2023 (2), U10CA180886 (2), U24CA196172 (2), UL1RR024150 (2), 2005 (1), 2016 (1), 2019 (1), K23CA178183 (1), P30CA036727 (1)